Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial

Phase 1 Trial Success:
Terns Pharmaceuticals' oral GLP-1R agonist, TERN-601, demonstrated statistically significant mean weight loss up to 5.5% over 28 days in a Phase 1 clinical trial.

Dose-Dependent Efficacy:
The trial showed dose-dependent, statistically significant placebo-adjusted mean weight loss across all three doses evaluated, with the highest dose of 740 mg QD resulting in a peak-adjusted weight loss of 4.9%.

Tolerability:
TERN-601 was well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations, even with rapid dose titration.

Future Plans:
Terns plans to initiate Phase 2 clinical trials for TERN-601 in 2025, aiming to further evaluate its efficacy and safety in treating obesity.

Potential Combination Therapy:
TERN-601 may be used as monotherapy or in combination with other agents, such as TERN-501, a clinical-stage THR-β agonist, or a GIPR modulator from the TERN-800 series.